Why is Summit Therapeutics stock climbing today?
Summit Therapeutics (SMMT) stock rose 1.1% in pre-market trading after Bernstein upgraded it to Market Perform with a $11.90 price target, citing a valuation reset for its drug ivonescimab. The firm assigned a 35% probability of success for the ILLUMINE Phase 3 trial. The stock is near its 52-week low and 57% below its high. The FDA's review of ivonescimab is a long-term catalyst. The broader market is also up, supporting risk assets like biotechs.
How this was made
The 30-second read
Why it matters
The upgrade provides a short‑term catalyst, but long‑term upside depends on trial outcomes and FDA approval.
Market read
The upgrade sparked a modest pre‑market rally, highlighting the stock's sensitivity to analyst actions.
What to watch
Potential trial failures in urothelial or head‑and‑neck cancers could pressure the stock.
Background
Summit Therapeutics is a clinical‑stage biotech with a single late‑stage candidate, ivonescimab.
Ticker impact
Bernstein SocGen upgraded Summit Therapeutics to Market Perform and raised the price target, driving a 1.1% pre‑market rise.
modest upside in the next few days as investors re‑price the stock near the new target.
The upgrade is a fresh catalyst with a concrete price‑target lift, likely to attract momentum traders.
Market effects
May lift sentiment for other late‑stage oncology biotechs.
Limited to US biotech sector.
Minimal global impact.
Counterpoint
Upgrade may be premature given ivonescimab's limited market potential versus Keytruda.
Key entities
- analystBernstein SocGen
Research firm that issued the upgrade.
- drugivonescimab
Summit's sole late‑stage PD‑1 bispecific antibody.
